1y return+65.4%S&P 500 +20.9%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since June 30, 2024: $160 against $137 in the S&P 500.2
Lion Point Capital, LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| CUECue Biopharma Inc | $1.7M | 8.0% | New |
| PRAXPraxis Precision Medicines I | $1.5M | 7.1% | |
| MLTXMoonlake Immunotherapeutics | $1.3M | 6.3% | |
| FENCFennec Pharmaceuticals Inc | $1.2M | 5.8% | |
| Royalty Pharma PLCCUSIP G7709Q104 | $1.2M | 5.7% | |
| CMPSCompass Pathways PLC | $1.1M | 5.4% | |
| MISTMilestone Pharmaceuticals In | $1.1M | 5.3% | |
| BNTCBenitec Biopharma Inc | $830K | 4.0% | |
| SNDXSyndax Pharmaceuticals Inc | $787K | 3.8% | |
| Biohaven LtdCUSIP G1110E107 | $769K | 3.7% | |
| GERNGeron Corp | $740K | 3.5% | |
| Uniqure NvCUSIP N90064101 | $677K | 3.2% | |
| ARDXArdelyx Inc | $656K | 3.1% | |
| LNTHLantheus Hldgs Inc | $610K | 2.9% | |
| IRONDisc Medicine Inc | $592K | 2.8% | |
| SRPTSarepta Therapeutics Inc | $512K | 2.4% | |
| HUMAHumacyte Inc | $507K | 2.4% | |
| KURAKura Oncology Inc | $505K | 2.4% | |
| VTRSViatris Inc | $440K | 2.1% | |
| DYNDyne Therapeutics Inc | $400K | 1.9% | |
| BBIOBridgebio Pharma Inc | $372K | 1.8% | |
| EWTXEdgewise Therapeutics Inc | $370K | 1.8% | |
| PCRXPacira Biosciences Inc | $342K | 1.6% | |
| RGNXRegenxbio Inc | $319K | 1.5% | |
| RCKTRocket Pharmaceuticals Inc | $294K | 1.4% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| ARDXArdelyx Inc | September 30, 2022 | +328.6% | $656K |
| BBIOBridgebio Pharma Inc | June 30, 2024 | +194.0% | $372K |
| ARQTArcutis Biotherapeutics Inc | September 30, 2024 | +181.9% | $138K |
| MLTXMoonlake Immunotherapeutics | September 30, 2025 | +171.5% | $1.3M |
| CMPSCompass Pathways PLC | September 30, 2025 | +146.9% | $1.1M |
| Gh Research PLCCUSIP G3855L106 | December 31, 2025 | +111.7% | $274K |
| MLYSMineralys Therapeutics Inc | March 31, 2024 | +109.0% | $283K |
| Uniqure NvCUSIP N90064101 | December 31, 2025 | +92.5% | $677K |
| LNTHLantheus Hldgs Inc | December 31, 2025 | +66.7% | $610K |
| EWTXEdgewise Therapeutics Inc | December 31, 2025 | +63.7% | $370K |
Sold off last quarter
- Cue Biopharma IncCUSIP 22978P106 was $506K
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +18.5% | +14.8% |
| March 31, 2026 | −7.4% | −4.6% |
| December 31, 2025 | +11.8% | +2.4% |
| September 30, 2025 | +34.7% | +7.8% |
| June 30, 2025 | +9.8% | +10.5% |
| March 31, 2025 | −14.4% | −4.6% |
| December 31, 2024 | −2.9% | +2.1% |
| September 30, 2024 | +5.7% | +5.4% |
| March 31, 2024 | +9.6% | +10.0% |
| December 31, 2023 | −0.5% | +11.2% |
| September 30, 2023 | −6.1% | −3.6% |
| June 30, 2023 | +10.8% | +8.3% |
| March 31, 2023 | +6.2% | +7.0% |
| December 31, 2022 | −4.9% | +7.1% |
| September 30, 2022 | +6.8% | −5.3% |
| June 30, 2022 | −8.8% | −16.5% |
| March 31, 2022 | −8.4% | −4.9% |
| December 31, 2021 | −3.6% | +10.7% |
| September 30, 2021 | −12.9% | +0.3% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Lion Point Capital, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1643354&type=13F-HR&dateb=&owner=include&count=40CIK 1643354
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1643354/000101359426000908/Filed August 14, 2026 · accession 0001013594-26-000908